1 Updates

Paid Rheumatoid Arthritis (RA) Clinical Trial Now Enrolling at Achieve Clinical Research in Birmingham, Alabama; Accepting M/F Patients with RA Age 18 - 75

Oct 16 2013, 4:18pm CDT | by PR.com

Achieve is conducting a study to evaluate the safety and efficacy of a new drug versus rituximab in patients with moderately to severely active rheumatoid arthritis (RA).

Birmingham, AL, October 16, 2013 --(PR.com)-- *To see if you qualify for this RA Clinical Trial in Alabama, visit Achieve Clinical Research on the web (http://www.achieveclinical.com/). There is no...

Filed under: news

Full Story below YouTube Videos

 
 

 

26 weeks ago

Paid Rheumatoid Arthritis (RA) Clinical Trial Now Enrolling at Achieve Clinical Research in Birmingham, Alabama; Accepting M/F Patients with RA Age 18 - 75

Oct 16 2013, 4:18pm CDT | by PR.com

Achieve is conducting a study to evaluate the safety and efficacy of a new drug versus rituximab in patients with moderately to severely active rheumatoid arthritis (RA).

Birmingham, AL, October 16, 2013 --(PR.com)-- *To see if you qualify for this RA Clinical Trial in Alabama, visit Achieve Clinical Research on the web (http://www.achieveclinical.com/). There is no cost to participate, no insurance is required, and you may receive compensation for time and travel.

Study Design

This is a 48-week, double-blind, multiple dose, parallel group trial to compare the safety, efficacy, immunogenicity and tolerability of an experimental drug to Rituxan and MabThera in patients with moderately to severely active RA. Patients will be enrolled across 250 clinical sites, in 26 countries.

Part I (48-week duration) will include 150 patients, which is considered sufficient for pharmacokinetics (PK) testing. Part II consists of a 48-week comparative safety/efficacy analyses with an additional 150 patients.

Background & Rationale

Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease characterized by synovial inflammation in the joints and consequently, progressive joint destruction. Depending on the severity of the disease, systemic manifestations may occur including lung disease, rheumatoid nodules and cardiovascular system effects. Without effective RA treatment, this disease may lead to severe functional disabilities, and therefore a considerable reduction in quality of life for the patient. The prevalence of RA varies with factors such as gender, race and smoking status and is approximately 0.5-1%.

B lymphocytes (B cells) are thought to play a crucial role in the pathogenesis of RA. They are also the primary source of rheumatoid factors (RFs) and anti-cyclic citrullinated peptide (anti-CCP) antibodies which contribute to the formation of immune complexes and complement activation in inflamed joints. Thus, B cell targeted therapy could play an important role in RA through a reduction in the B cell count as well as a reduction in B cell-mediated downstream effects on other cell types involved in the inflammatory response.

Primary Objectives

The primary objectives of this trial are:

To show PK similarity of this new drug to MabThera and Rituxan and of Rituxan to MabThera (three-way PK similarity).
To establish statistical equivalence of efficacy of this new drug and Rituxan/MabThera, in patients with moderately to severely active RA

Inclusion Criteria

Male or female participants, between 18 and 80 years of age, who have a diagnosis of moderately to severely active RA for at least 6 months

Patients must have had an inadequate response or intolerance to conventional DMARD therapy including at least one TNF inhibitor.

Positive for RF and/or anti-CCP antibodies.

Current treatment for RA on an outpatient basis:

-- Must be currently receiving and tolerating oral or parenteral MTX therapy at a dose of 15-25 mg per week (dose may be as low as 10 mg per week if the patient is unable to tolerate a higher dose) for at least 12 weeks immediately prior to Day 1.

-- Patients must be willing to receive oral folic acid (at least 5 mg/week or as per local practice) or equivalent during the entire study (mandatory co-medication for MTX treatment).

-- Biologic agents and DMARDs (other than MTX) must be withdrawn at least 2 weeks prior to Day 1.

-- Leflunomide must be withdrawn at least 8 weeks prior to Day 1 or a minimum of 2 weeks prior to Day 1 if after 11 days of standard cholestyramine washout.

-- If receiving current treatment with oral corticosteroids (other than intra-articular or parenteral), the dose must not exceed 10 mg/day prednisolone or equivalent. During the 4 weeks prior to Baseline (Day 1) the dose must remain stable.

-- Intra-articular and parenteral corticosteroids are not permitted within 6 weeks prior to Baseline Day 1 or throughout the trial, with the exception of IV administration of 100 mg methylprednisolone 30 to 60 minutes prior to each infusion
as this is part of the trial procedures.

-- Any concomitant non-steroidal anti-inflammatory drugs (NSAIDs) must be stable for at least 2 weeks prior to Day 1.

-- Patients may be taking oral hydroxychloroquine provided that the dose is not greater than 400 mg/day or chloroquine provided that the dose is not greater than 250 mg/day.

*Achieve Clinical Research conducts Phase II-IV Clinical Trials in Alabama. For more information about participating in an RA Clinical Study, please visit our website or contact us directly at (205) 380-6434.

Contact Information:
Achieve Clinical Research
Lashondra Cade
(205) 380-6434 320
Contact via Email
www.achieveclinical.com

Read the full story here: http://www.pr.com/press-release/520216

Press Release Distributed by PR.com

Source: PR.com

 

Don't miss ...

 

blog comments powered by Disqus

Latest stories

The Newest Addition to CreateASoft's Dynamic Process Improvement Simulators
Introducing Simcad Pro Lite, the newest addition to CreateASoft's next generation software that empowers process improvement initiatives through dynamic simulation.
 
 
FieldSync™ Releases Version 3.0
File Management and a New Mobile App Lead Exciting Changes in v3.0.
 
 
The Lowry Team of Keller Williams Opens a New Mega Agent Office in West Chester
The Lowry Team of Keller Williams Opens a New Mega Agent Office in West Chester, Ohio. The new office is located at 8833 Cincinnati Dayton Road, Suite 201 West Chester, Ohio 45069. The office is conveniently located in the heart of Olde West Chester.
 
 
Really Epic Ventures Awards Utah Entrepreneur Challenge "Innovator Sponsorship" Prize Package to Alterniity
Startup Company Seeking to Deliver Non-Pharmacuetical Alzheimer’s Treatment Wins $150,000 Worth of In-Kind Sponsorship Funds from Really Epic Ventures
 
 
 

Latest from the Network

Apple Now Recycling All Apple Gadgets At Retail Stores
Apple has big things in the works for Earth Day, including their most recent announcement that their retail stores will start recycling all of their gadgets. Apple is calling it “free, responsible recycling” that will...
Read more on Apple Balla
 
Solaire Shines Light On Philippine Casino Ambitions
The Philippines hopes to be the next big thing in Asian gaming, and its biggest step toward that goal just completed its first year of operation. Solaire Resort and Casino opened in March last year (see page 77; payment...
Read more on Business Balla
 
Jay Z and Beyonce buy London home?
Jay Z and Beyonce have bought a $9.3 million home in London. The superstar couple have reportedly splashed out on a luxury detached townhouse in west London, having looked for properties in the trendy Mayfair area and...
Read more on Celebrity Balla
 
Aaron Sorkin Gives More Details On Jobs Movie
The upcoming Steve Jobs movie based on the Walter Isaacson biography is still in the works, with Aaron Sorkin in charge of writing the script. Unfortunately, that is almost all that we currently know about the film.He...
Read more on Apple Balla
 
Innovators In The UK: Male, Affluent And Long-Term Planners
For decades, innovation policy has been the domain of technocrats and of party–political consensus. Whilst in other fields – such as science – regular surveys help inform public debate and policy-making, there has been...
Read more on Business Balla
 
Cameron Diaz planning holiday for Gwyneth Paltrow
Cameron Diaz is organizing a girls' holiday to help Gwyneth Paltrow get over her marriage split. The 'Other Woman' actress is keen to cheer up her friend following the end of her 10-year marriage to Chris Martin and is...
Read more on Celebrity Balla
 
Want To Earn $5,000? Stop Working
If you work for Amazon, Jeff Bezos will pay you a bonus of up to $5,000.  Generous, right?  And what do you have to do to get the bonus? Quit your job. It may seem crazy, but it’s true – a recent article in Time notes...
Read more on Business Balla
 
Your Local Mall, Re-digitized
As part of the never-ending battle for the consumer dollar, General Growth Properties, which owns some 120 high-end malls through the U.S., has recruited RetailMeNot to its side. Under a new agreement the two announced...
Read more on Business Balla
 
Jon Hamm slams Justin Bieber
Jon Hamm has branded Justin Bieber a "sh**head." The 'Mad Men' star thinks the 20-year-old singer - who is facing charges for Driving Under the Influence (DUI), resisting arrest and possessing an invalid driver's...
Read more on Celebrity Balla
 
 
Auto Balla Sexy Balla Sport Balla TV Balla Politics Balla Movie Balla Apple Balla Business Balla Ad Balla Celebrity Balla